<<Print>>

The Food and Drugs Authority (FDA) has cautioned the public, particularly hospitals, clinics and pharmacies, against stocking and dispensing an unregistered antibiotic, Ciprobiotic 250. �Hospitals, clinics and pharmacies having stocks of Ciprobiotic 250 (Ciprofloxacin Oral suspension 250mg/5ml) are advised to immediately hand them over to any of the FDA offices nationwide,� the authority said in a statement. It assured the public of its resolve to protect public health and safety. It said the drug was being imported and distributed on the Ghanaian market by Kojach Limited. �The product, Ciprobiotic 250, has not undergone the necessary evaluations by the FDA, hence the authority cannot guarantee its quality, safety and efficacy,� it said. The statement further said information on the packaging of the product indicated that it was manufactured in India by Fredun Pharmaceuticals Limited for Kojach Limited. Ciprofloxacin is an antibiotic used to treat different types of bacterial infections, including skin infections, urinary tract infections, gonorrhoea and typhoid fever.